)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ReproCELL Incorporated
ReproCELL Incorporated (4978) investor relations material
ReproCELL Incorporated Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2027 earnings summary12 Nov, 2026
Executive summary
H1 FY2027 revenue rose 18.7% YoY to ¥1,156m; operating loss narrowed to ¥497m, ordinary loss to ¥318m and net loss to ¥319m.
Research support delivered segment profit, while medical activities remained loss-making; full-year guidance was unchanged.
Financial highlights
Revenue was ¥1,156m vs ¥974m YoY; operating loss ¥497m vs ¥546m, ordinary loss ¥318m vs ¥483m and net loss ¥319m vs ¥486m.
Comprehensive income was ¥319m, compared with a ¥309m comprehensive loss in the prior-year interim period, including ¥649m in other securities valuation gains.
H1 EPS was -¥3.24 vs -¥5.14 YoY; FY forecast EPS is -¥4.47, based on a projected weighted-average 102.469m shares.
Outlook and guidance
FY2027 guidance remains revenue ¥2,629m, operating loss ¥630m, ordinary loss ¥458m and net loss ¥458m; no revisions were made.
Full-year EPS forecast reflects share-count increases from equity placements; further warrant exercises are excluded from the estimate.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ReproCELL Incorporated
- Net sales up 14.9% YoY, losses narrowed, and new capital raised for clinical trials and R&D.4978
Q1 2027 - Sales and profits declined sharply, with losses deepening and forecasts revised downward.4978Q3 2026
- Revenue declined 26% with deepening losses, but cash and equity remain strong.4978Q2 2026
- Revenue fell 23% and losses widened, but cash reserves and R&D investments remain robust.4978Q1 2026
- Revenue and net income increased, with strong growth in iPS and biotherapeutics segments.4978Q2 2025
- Revenue up 22.7% and net income positive, but losses expected next year as R&D ramps up.4978Q4 2025
- Revenue up 16.4% with narrowed losses; research support drives growth, medical profit falls.4978Q3 2025
Next ReproCELL Incorporated earnings date
Q3 20278 Feb, 2027
ReproCELL Incorporated
Next ReproCELL Incorporated earnings date
Q3 20278 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ReproCELL Incorporated is a biotechnology company focused on advancing stem cell research and drug discovery. The company specializes in providing services and products for stem cell research, including iPSC-derived cell lines, media, and other culture reagents. It also offers predictive drug discovery services utilizing human tissues. ReproCELL's offerings support both preclinical and clinical research, with services tailored to meet regulatory standards across various global markets. Its portfolio includes advanced solutions for gene editing, stem cell therapy, and 3D cell culture systems, which cater to a wide range of scientific and medical applications. The company is headquartered in Yokohama, Kanagawa, Japan, and its shares are listed on the Tokyo Stock Exchange.